JP Morgan Chase
DICE

JP Morgan Chase’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

JP Morgan Chase’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-126,300
Closed -$5.87M – 7859
2023
Q2 		$5.87M Buy
+126,300
New +$4.37M ﹤0.01% 2736
2022
Q4 		– Sell
-58,200
Closed -$1.18M – 7205
2022
Q3 		$1.18M Buy
58,200
+23,200
+66% +$423K ﹤0.01% 3877
2022
Q2 		$543K Buy
+35,000
New +$602K ﹤0.01% 4504

JP Morgan Chase's DICE Position: Q3 2023 in Review

JP Morgan Chase sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 618,089 shares — an estimated $28.7M sold.

JP Morgan Chase first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $28.7M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • JP Morgan Chase reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • JP Morgan Chase sold 618,089 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $28.7M.
  • JP Morgan Chase first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • JP Morgan Chase's DICE Therapeutics, Inc. Common Stock position peaked at $28.7M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.